Clinical Trials
2 trialsNCT05429905 2023-03-09
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
KK Women's and Children's Hospital
Phase 1/2 Unknown
NCT03636685 2018-08-17
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
ChineseAMS
Phase 1/2 Unknown